ArticleBMC microbiology2025
Epigenetic modulation of Ceratorhiza hydrophila by 5-azacytidine enhances antifungal metabolite production: insights from antimicrobial, metabolic, genomic and computational analyses.
Article in BMC microbiology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Nicotinamide and Sodium Butyrate Double the Pool of Treatment-Exclusive Metabolites in the Endophytic Fungus Curvularia sp. G6-32.Chemistry & biodiversity · 2026Article
- Biodiversity-Driven Natural Products and Bioactive Metabolites.Plants (Basel, Switzerland) · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe emergence of drug-resistant pathogens has stimulated the need for the development of new antimicrobial agents. Epigenetic modulation by suppressing epigenetic inhibitors, such as 5-azacytidine (5-aza), has been shown to activate silent biosynthetic gene clusters within a fungus and causes the production of novel secondary metabolites. This research examined this epigenetic modification strategy in the poorly studied filamentous fungus, Ceratorhiza hydrophila, which may help induce the additional production of bioactive compounds.
resultsThe results from genomic and spectroscopic analyses (ISSR profiling and FTIR spectroscopy) indicated that 50 µM 5-aza produced substantial global DNA demethylation and genomic changes in C. hydrophila with no impact on cell viability. The epigenetic changes associated with the DNA demethylation prompted a notable and selective change in antimicrobial profile to suppress antibacterial activity against strains such as Clostridium sporogenes while also showing a robust induction of antifungal activity against Candida albicans (22 mm inhibition zone). GC-MS was performed for a deep-dive characterization of the metabolic profile which revealed, for example, a dramatic alteration of the profile including production of new secondary metabolites such as a novel indole derivative and diisooctyl phthalate, which did not exist in the untreated control. In silico analyses, such as modelling the promoter and molecular docking opportunities, offered a believable mechanistic rationale for the effects seen, linked to the predicted modulation of primary biosynthetic pathways.
conclusionThis study demonstrates that epigenetic modulation can be used to successfully unlock latent biosynthetic capability in C. hydrophila resulting in the production of unique compounds with strong and selective antifungal activity. These results demonstrate the advantages of epigenetic screening of unique fungal sources in the search for new drug leads.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.